Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients

被引：1

作者：

Sento, Shinya ^{[1
]}

Kitamura, Naoya ^{[1
]}

Yamamoto, Tetsuya ^{[1
]}

Nakashiro, Koichi ^{[2
]}

Hamakawa, Hiroyuki ^{[2
]}

Ibaragi, Soichiro ^{[3
]}

Sasaki, Akira ^{[3
]}

Takamaru, Natsumi ^{[4
]}

Miyamoto, Yoji ^{[4
]}

Kodani, Isamu ^{[5
]}

Ryoke, Kazuo ^{[5
]}

Mishima, Katsuaki ^{[6
]}

Ueyama, Yoshiya ^{[6
]}

机构：

[1] Kochi Univ, Dept Oral & Maxillofacial Surg, Kochi Med Sch, Oko Cho, Nankoku, Kochi 7838505, Japan

[2] Ehime Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Toon, Japan

[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral & Maxillofacial Surg, Okayama, Japan

[4] Tokushima Univ, Div Integrated Sci Translat Res, Subdiv Mol Oral Med, Dept Oral Surg,Inst Biomed Sci,Grad Sch, Tokushima, Japan

[5] Tottori Univ, Div Oral & Maxillofacial Biopathol Surg, Dept Med Sensory & Motor Organs, Sch Med,Fac Med, Yonago, Tottori, Japan

[6] Yamaguchi Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Yamaguchi, Japan

来源：

ANTICANCER RESEARCH | 2017年 / 37卷 / 12期

关键词：

Chemotherapy; nausea; vomiting; antiemetic therapy; oral cancer; palonosetron; PHASE-II;

D O I：

10.21873/anticanres.12165

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients. Patients and Methods: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy. Results: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase. During the acute phase, 86 of 87 courses (98.9%) had CR and 84 of 87 courses (96.6%) had CC. During the delayed phase, 84 of 87 courses (96.6%) had CR and 70 of 87 courses (80.5%) had CC. Conclusion: Palonosetron is effective at preventing HEC-induced chemotherapy-induced nausea and vomiting (CINV) in oral cancer chemotherapeutic regimens in the acute and delayed phases.

引用

页码：6977 / 6981

页数：5

共 50 条

[1] REDUCED RISK OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PATIENTS WITH CANCER TREATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY AND ANTIEMETIC PROPHYLAXIS WITH PALONOSETRON
Schwartzberg, L.
Jackson, J.
Jain, G.
Balu, S.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A434 - A434
[2] COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY
Rely, K.
Pierre, K. A.
Salinas, E. G.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A496 - A496
[3] Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer
Navari, Rudolph M.
[J]. FUTURE ONCOLOGY, 2010, 6 (07) : 1073 - 1084
[4] A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy
Takahashi, Tsutomu
Okada, Takahiro
Ikejiri, Fumiyoshi
Ito, Shunsuke
Okada, Yusuke
Takahashi, Fumimasa
Kumanomido, Satoshi
Jo, Yumi
Adachi, Koji
Onishi, Chie
Kawakami, Koshi
Miyake, Takaaki
Inoue, Masaya
Suzuki, Ritsuro
Suzumiya, Junji
[J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (01) : 189 - 194
[5] A prospective study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in malignant lymphoma patients following highly emetogenic chemotherapy
Tsutomu Takahashi
Takahiro Okada
Fumiyoshi Ikejiri
Shunsuke Ito
Yusuke Okada
Fumimasa Takahashi
Satoshi Kumanomido
Yumi Jo
Koji Adachi
Chie Onishi
Koshi Kawakami
Takaaki Miyake
Masaya Inoue
Ritsuro Suzuki
Junji Suzumiya
[J]. International Journal of Clinical Oncology, 2018, 23 : 189 - 194
[6] Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer
Murakami, Michiyasu
Hashimoto, Hiroki
Yamaguchi, Kyohei
Yamaguchi, Ikuko
Senba, Shozo
Siraishi, Takeshi
[J]. SUPPORTIVE CARE IN CANCER, 2014, 22 (04) : 905 - 909
[7] Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer
Michiyasu Murakami
Hiroki Hashimoto
Kyohei Yamaguchi
Ikuko Yamaguchi
Shozo Senba
Takeshi Siraishi
[J]. Supportive Care in Cancer, 2014, 22 : 905 - 909
[8] The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
Miura, Satoru
Watanabe, Satoshi
Sato, Kazuhiro
Makino, Masato
Kobayashi, Osamu
Miyao, Hiromi
Iwashima, Akira
Okajima, Masaaki
Tanaka, Junta
Tanaka, Hiroshi
Kagamu, Hiroshi
Yokoyama, Akira
Narita, Ichiei
Yoshizawa, Hirohisa
[J]. SUPPORTIVE CARE IN CANCER, 2013, 21 (09) : 2575 - 2581
[9] The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy
Satoru Miura
Satoshi Watanabe
Kazuhiro Sato
Masato Makino
Osamu Kobayashi
Hiromi Miyao
Akira Iwashima
Masaaki Okajima
Junta Tanaka
Hiroshi Tanaka
Hiroshi Kagamu
Akira Yokoyama
Ichiei Narita
Hirohisa Yoshizawa
[J]. Supportive Care in Cancer, 2013, 21 : 2575 - 2581
[10] Ramosetron versus palonosetron in combination with aprepitant and dexamethasone for the control of highly emetogenic chemotherapy-induced nausea and vomiting
Kwon, J. H.
Kang, J-H.
Lee, Y-G.
Park, K. U.
An, H. J.
Sohn, J.
Seol, Y. M.
Lee, H.
Yun, H-J.
Ahn, J. S.
Kim, H. J.
[J]. ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →